HC Wainwright Has Optimistic Outlook of DNLI FY2028 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – HC Wainwright lifted their FY2028 EPS estimates for shares of Denali Therapeutics in a report released on Tuesday, January 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn $4.16 per share for the year, up from their previous forecast of $3.98. HC Wainwright currently has a “Buy” rating and a $87.00 price objective on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2029 earnings at $6.29 EPS.

A number of other brokerages have also recently commented on DNLI. Jefferies Financial Group lifted their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Baird R W raised Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research report on Monday, December 16th. JPMorgan Chase & Co. dropped their target price on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Robert W. Baird initiated coverage on Denali Therapeutics in a report on Tuesday. They set an “outperform” rating and a $31.00 price target on the stock. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $38.91.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $21.25 on Wednesday. The stock has a market capitalization of $3.06 billion, a PE ratio of -7.70 and a beta of 1.39. The company’s fifty day moving average is $24.34 and its 200 day moving average is $24.88. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the firm posted ($0.72) earnings per share.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares of the company’s stock, valued at approximately $6,529,495.83. This trade represents a 14.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Vicki L. Sato sold 1,020 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the sale, the director now owns 111,056 shares of the company’s stock, valued at approximately $3,331,680. This represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 104,518 shares of company stock valued at $2,576,982 in the last three months. Company insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC raised its stake in shares of Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after acquiring an additional 7,596,508 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Denali Therapeutics by 63.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock worth $109,223,000 after purchasing an additional 1,451,770 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Denali Therapeutics during the second quarter worth $24,454,000. Wellington Management Group LLP lifted its holdings in shares of Denali Therapeutics by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after purchasing an additional 903,683 shares during the last quarter. Finally, Integral Health Asset Management LLC purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at $7,546,000. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.